2FDA.Guidance for Industry.Premarketing risk assessment (premarketing guidance)[EB/OL].http://www,fda.gov,2007-03-20.
3FDA.Guidance for Industry.Development and use of risk minimization action plans (riskMAP guidance)[EB/OL].http://www.fda.gov,2007-04-11.
4EMEA Guidelines on risk management systems for medicinal products for human use.http://www,emea.europa,eu,2007-04-15.
5Mcbride W G.Thalidomide and congenital abnormalities[J].Lancet,19611 Ⅰ,271.
6Wiholm B-E,Olsson S,Moore N,et al.Spontaneous reporting systems outside the US[J].Pharmacoepidemiology(3rd ed):Strom B.John Wiley & Sons,Ltd,Chichester,2000,175-192.
7Almenoff J,Tonning J M,Lawrence Gould A,et al.Perspectives on the use of data mining in Pharmacovigilance[J].Drug Safety,2005,28 (11):981-1007.
8EMEA.Guideline on the use of statistical signal detection methods in the Eudravigilance DataAnalysisSystem[EB/OL].http://www.emea.europa.eu/pdfs/human/phvwp/10646406enfin.pdf,London,26June 2008.Doc.Ref.EMEA/106464/2006 rev.
9MORSE MA,,CALIFF RM,SUGARMANJ.Monitoring and ensu-ring safety during clinical research[].The Journal of The American Medical Association.2002
